Compare Figs Inc (FIGS) vs 10X Genomics Inc (TXG) Price & Performance

FIGS trades at $9.72, down 2.8% today, amid bearish technical signals despite recent earnings beats. Revenue grew to $631M in 2025 with a 66.6% gross margin, but net cash flow remains negative. Analyst consensus is bullish with a $19.50 price target, though technical indicators show selling pressure with RSI at neutral levels and ADX signaling a strong downtrend.

The stock presents a growth opportunity with strong fundamentals and analyst support, but faces near-term technical headwinds and margin pressures from tariffs and freight costs. Investors should weigh the 100% upside to consensus target against execution risks and persistent negative cash flow trends.

TXG is trading at $45.80, up 9.65% today, showing strong momentum despite mixed analyst sentiment. The stock exhibits bullish technical signals with positive moving averages, though RSI levels suggest potential overbought conditions. Fundamentally, the company continues to report revenue growth with improving margins, narrowing losses from -$166M in 2022 to -$44M in 2025. Recent developments include strategic acquisitions and research collaborations that strengthen its life sciences technology position.

The outlook remains cautiously optimistic as TXG demonstrates operational improvement and strategic positioning in genomics technology. Key opportunities include continued margin expansion and platform adoption, while risks involve persistent profitability challenges and competitive pressures. Analyst consensus shows divided opinions with a $37.71 price target below current levels, suggesting potential near-term volatility despite long-term growth prospects.